I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Saturday, March 14, 2020

The Catherine S. Eberly Center for Women forum on Triple Negative Breast Cancer 2020

Speaking on my TNBC diagnosis
On February 25, 2020, I was asked to speak as a Triple Negative Breast Cancer survivor and as an advocate at a forum at The University of Toledo's The Catherine S. Eberly Center for Women.  This forum was in honor of Black History Month, bringing awareness to Triple Negative Breast Cancer that disproportionately affect African American women.







Mary Westphal – Executive Director, Susan G. Komen Northwest Ohio
Dr. Marlene Welch – plastic surgeon serving breast cancer survivors
Dr. Alexzander Asea – Professor, Dept. of Medicine (precision medicine researcher)
Melissa Paskvan – TNBC survivor and advocate
Dr. Kim Jenkins – Assoc. Prof., Anesthesiology and Assoc. Dean for Diversity and Inclusion

Total Pageviews



"click image to link"